20.4 C
New York
Sunday, June 7, 2026

Tag: early stage

NANO Nuclear Reports Third Fiscal Quarter 2025 Financial Results and Provides Business Update

New York, N.Y., Aug. 14, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today reported its third fiscal quarter financial results and provided a business update.

Nuclear Fuels Shareholders Approve Arrangement with Premier American Uranium

CSE:NFOTCQX:NFUNF TSXV:PUR OTCQB:PAUIF VANCOUVER, BC, Aug. 13, 2025 /PRNewswire/ - Nuclear Fuels Inc. ("Nuclear Fuels" or the "Company") (CSE: NF) (OTCQX: NFUNF) and Premier American Uranium...

Nuclear Fuels Shareholders Approve Arrangement with Premier American Uranium

CSE:NFOTCQX:NFUNF TSXV:PUR OTCQB:PAUIF VANCOUVER, BC, Aug. 13, 2025 /CNW/ - Nuclear Fuels Inc. ("Nuclear Fuels" or the "Company") (CSE: NF) (OTCQX: NFUNF) and Premier American Uranium...

FIEE Announces Fiscal 2025 First Half Unaudited Financial Results

First Half Revenue of $45,118Prepaid subscription fees received from customers for our SaaS service were $1.5 Million. HONG KONG, Aug. 13, 2025 /PRNewswire/ -- FiEE,...

AVANT BIO and Portfolio Company Intrepid Labs Earn Nominations for Prestigious Prix Galien USA Awards

AVANT BIO nominated by the prestigious Foundation Galien for the Prix Galien Award in the "Incubators, Accelerators and Equity" category.Unique distinction of having a portfolio...

NANO Nuclear Energy to Attend Upcoming Industry Focused Investor Conferences

New York, N.Y., Aug. 13, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced its attendance at several upcoming industry focused investor events.

Prairie Provident Announces Second Quarter 2025 Results

CALGARY, Alberta, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident" or the "Company") (TSX:PPR) announces its financial and operating results for the second quarter of 2025. The Company’s interim financial statements for the three and six months ended June 30, 2025 and related Management’s Discussion and Analysis (“MD&A”) are available on our website at www.ppr.ca and filed on SEDAR+ at www.sedarplus.ca.

EMP METALS REPORTS SUBSTANTIAL INCREASE IN HIGH-GRADE RESOURCE ACROSS ALL CATEGORIES FOR ITS VIEWFIELD AND MANSUR PROJECTS, SASKATCHEWAN

VANCOUVER, BC, Aug. 12, 2025 /CNW/ - EMP Metals Corp. (CSE: EMPS) (OTCQB: EMPPF) ("EMP" or the "Company") is pleased to report an increase and...

Claros Technologies Secures $10 Million in Convertible Note Financing to Accelerate Global Deployment of ClarosTechUV™ PFAS Destruction Technology

Strategic mix of investors fuels next phase of Claros' growth after breakthrough pilot with Daikin America, Inc. MINNEAPOLIS, Aug. 12, 2025 /PRNewswire/ -- Claros Technologies,...

Claros Technologies Secures $10 Million in Convertible Note Financing to Accelerate Global Deployment of ClarosTechUV™ PFAS Destruction Technology

Strategic mix of investors fuels next phase of Claros' growth after breakthrough pilot with Daikin America, Inc. MINNEAPOLIS, Aug. 12, 2025 /PRNewswire/ -- Claros Technologies,...

LYNO AI Presale Advances With Over 259K Tokens Sold in Early Stage Offering        

ROAD TOWN, British Virgin Islands, Aug. 11, 2025 (GLOBE NEWSWIRE) -- LYNO AI is enjoying unprecedented interest with early adopters and whales rushing to participate in the soon to be over presale. The Early Bird presale has inspired high levels of investor confidence as over 259,000 tokens have been sold in a very short period of time.

Hampton Financial Corporation Announces The Completion of A Non-Brokered Private Placement of Debentures

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs)

Forte Medical National Survey Announcement

UK MedTech company launches patient experience survey around overlooked & unreliable Urinary Tract Infection and prenatal screening diagnostics.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEarly stage